235 related articles for article (PubMed ID: 33547022)
21. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cortes JE; Heidel FH; Hellmann A; Fiedler W; Smith BD; Robak T; Montesinos P; Pollyea DA; DesJardins P; Ottmann O; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Heuser M
Leukemia; 2019 Feb; 33(2):379-389. PubMed ID: 30555165
[TBL] [Abstract][Full Text] [Related]
23. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
[TBL] [Abstract][Full Text] [Related]
24. [European approvals: Glasdegib for Acute myeloid leukemia].
Barrière S; Gastaud L
Bull Cancer; 2020 Dec; 107(12):1206-1207. PubMed ID: 33070952
[No Abstract] [Full Text] [Related]
25. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
[TBL] [Abstract][Full Text] [Related]
26. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Jaramillo S; Krisam J; Le Cornet L; Kratzmann M; Baumann L; Sauer T; Crysandt M; Rank A; Behringer D; Teichmann L; Görner M; Trappe RU; Röllig C; Krause S; Hanoun M; Hopfer O; Held G; Buske S; Fransecky L; Kayser S; Schliemann C; Schaefer-Eckart K; Al-Fareh Y; Schubert J; Geer T; Kaufmann M; Brecht A; Niemann D; Kieser M; Bornhäuser M; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Schlenk RF
Trials; 2021 Nov; 22(1):765. PubMed ID: 34732236
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Cortes JE; Heidel FH; Fiedler W; Smith BD; Robak T; Montesinos P; Candoni A; Leber B; Sekeres MA; Pollyea DA; Ferdinand R; Ma WW; O'Brien T; O'Connell A; Chan G; Heuser M
J Hematol Oncol; 2020 Jul; 13(1):92. PubMed ID: 32664995
[TBL] [Abstract][Full Text] [Related]
28. [New therapeutic agents for acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
[TBL] [Abstract][Full Text] [Related]
29. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Estey E; Karp JE; Emadi A; Othus M; Gale RP
Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
[TBL] [Abstract][Full Text] [Related]
30. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
Cortes JE; Candoni A; Clark RE; Leber B; Montesinos P; Vyas P; Zeidan AM; Heuser M
Leuk Lymphoma; 2020 Dec; 61(14):3287-3305. PubMed ID: 32967493
[TBL] [Abstract][Full Text] [Related]
31. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Sekeres MA; Schuster M; Joris M; Krauter J; Maertens J; Breems D; Gyan E; Kovacsovics T; Verma A; Vyas P; Wang ES; Ching K; O'Brien T; Gallo Stampino C; Ma WW; Kudla A; Chan G; Zeidan AM
Ann Hematol; 2022 Aug; 101(8):1689-1701. PubMed ID: 35488900
[TBL] [Abstract][Full Text] [Related]
32. Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date.
Iyer SG; Stanchina M; Bradley TJ; Watts J
Cancer Manag Res; 2022; 14():2267-2272. PubMed ID: 35937938
[TBL] [Abstract][Full Text] [Related]
33. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
34. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Sekeres MA; Montesinos P; Novak J; Wang J; Jeyakumar D; Tomlinson B; Mayer J; Jou E; Robak T; Taussig DC; Dombret H; Merchant A; Shaik N; O'Brien T; Roh W; Liu X; Ma W; DiRienzo CG; Chan G; Cortes JE
Leukemia; 2023 Oct; 37(10):2017-2026. PubMed ID: 37604981
[TBL] [Abstract][Full Text] [Related]
35. Update on glasdegib in acute myeloid leukemia - broadening horizons of Hedgehog pathway inhibitors.
Fersing C; Mathias F
Acta Pharm; 2022 Mar; 72(1):9-34. PubMed ID: 36651529
[TBL] [Abstract][Full Text] [Related]
36. Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient.
Fathi AT
Clin Cancer Res; 2019 Oct; 25(20):6015-6017. PubMed ID: 31324656
[TBL] [Abstract][Full Text] [Related]
37. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Griffiths EA; Carraway HE; Chandhok NS; Prebet T
Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
[TBL] [Abstract][Full Text] [Related]
38. New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Daver N; Wei AH; Pollyea DA; Fathi AT; Vyas P; DiNardo CD
Blood Cancer J; 2020 Oct; 10(10):107. PubMed ID: 33127875
[TBL] [Abstract][Full Text] [Related]
39. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.
Shallis RM; Bewersdorf JP; Boddu PC; Zeidan AM
Expert Rev Anticancer Ther; 2019 Aug; 19(8):717-729. PubMed ID: 31422721
[No Abstract] [Full Text] [Related]
40. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]